Business Description
Kiora Pharmaceuticals Inc
NAICS : 325413
SIC : 2835
ISIN : US30233M1071
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 22.94 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 64.9 | |||||
3-Year EPS without NRI Growth Rate | 68.9 | |||||
3-Year FCF Growth Rate | 68.6 | |||||
3-Year Book Growth Rate | -77.5 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 13.4 | |||||
9-Day RSI | 21.31 | |||||
14-Day RSI | 29.15 | |||||
6-1 Month Momentum % | -0.37 | |||||
12-1 Month Momentum % | -82.9 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.9 | |||||
Quick Ratio | 2.9 | |||||
Cash Ratio | 1.5 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -281.4 | |||||
Shareholder Yield % | -39.88 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -126.62 | |||||
ROA % | -73.88 | |||||
ROIC % | -81.87 | |||||
ROC (Joel Greenblatt) % | -10793.04 | |||||
ROCE % | -84.26 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 2.23 | |||||
PB Ratio | 0.73 | |||||
EV-to-EBIT | -1.04 | |||||
EV-to-EBITDA | -1.04 | |||||
EV-to-Forward-Revenue | 0.71 | |||||
EV-to-FCF | -1.35 | |||||
Earnings Yield (Greenblatt) % | -96.15 | |||||
FCF Yield % | -62.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Kiora Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.767 | ||
Beta | 0.03 | ||
Volatility % | 101.02 | ||
14-Day RSI | 29.15 | ||
14-Day ATR (€) | 0.018648 | ||
20-Day SMA (€) | 0.510625 | ||
12-1 Month Momentum % | -82.9 | ||
52-Week Range (€) | 0.403 - 4.35 | ||
Shares Outstanding (Mil) | 26.26 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Kiora Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Kiora Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Kiora Pharmaceuticals Inc Frequently Asked Questions
What is Kiora Pharmaceuticals Inc(STU:7EY0)'s stock price today?
When is next earnings date of Kiora Pharmaceuticals Inc(STU:7EY0)?
Does Kiora Pharmaceuticals Inc(STU:7EY0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |